Menu
Latest Information
January 30th, 2018
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared with everolimus, according to a study published in the Journal of Clinical Oncology.1
December 15th, 2017
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
October 13th, 2017
Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic subtypes of the malignancy, new findings suggest.
Print this page Tell A Friend Add to Favorites

Latest Information


First | Prev | PAGE 1 of 8 | Next | Last
 
January 30th, 2018
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared with everolimus, according to a study published in the Journal of Clinical Oncology.1

December 15th, 2017
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.

October 13th, 2017
Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic subtypes of the malignancy, new findings suggest.

September 10, 2017
MADRID, Sept 10 (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

July 26th, 2017
Patients with metastatic renal cell carcinoma (RCC) had durable responses and manageable safety when treated with the combination of the immune checkpoint inhibitors nivolumab and ipilimumab, according to the results of the CheckMate 016 study published in the Journal of Clinical Oncology.


June 16th, 2017
Add greater risk of kidney and bladder cancer to the long list of why a lifetime of sitting on the sofa isn't good for your health, a new study suggests.


June 8th, 2017
Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma (RCC) who had undergone nephrectomy, according to the results of the phase III PROTECT trial (abstract 4507).

June 1st, 2017
The FDA has granted a priority review designation to sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence

February 8th, 2017
Patients with kidney tumors with pathology indicating a fumarate hydratase (FH) mutation should be referred for genetic testing, according to an article published in Cancer.1 Results from these tests can determine whether a patient and/or his or her family members should go on targeted surveillance for recurrent tumors.

December 19th, 2016
Statin use in patients with kidney cancer improved cancer-specific survival and overall survival, according to the results of a meta-analysis published recently in Cancer Treatment Reviews. There was, however, no effect on recurrence-free or progression-free survival

November 16, 2016
Among patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), first-line therapy with cabozantinib was superior to standard-of-care sunitinib with respect to objective response rate and progression-free survival, according to a study published in the Journal of Clinical Oncology

October 14th, 2016
Patients with aggressive forms of metastatic renal cell carcinoma (RCC) benefited more from treatment with cabozantinib (Cometriq) than with sunitinib (Sutent), according to a study reported here.

September 7th, 2016
Obesity is a risk factor for kidney cancer. Yet, obese people with advanced kidney cancer seem to live longer than normal-weight or underweight patients, a new study finds.

August 12th, 2016
Greater exposure to metalworking fluids (MWF), which are used to cool and lubricate metal in occupational settings, may increase the risk of renal cell carcinoma (RCC), especially among white men, researchers found.

August 9th, 2016
A phase 3 study of sunitinib in the adjuvant treatment setting in patients at high risk for recurrent renal cell carcinoma reached its primary end point.

August 04, 2016

Some patients with slow-growing metastatic renal cell carcinoma can be safely treated with a "watch and wait" approach, which allows them to avoid the toxicity of noncurative systemic therapy for months or even years, say researchers.

August 3rd, 2016
Undergoing complete metastasectomy for metastatic renal cell carcinoma (RCC) was associated with improved survival outcomes, according to the results of a meta-analysis published in the Journal of Urology.

June 8th, 2016.
Nivolumab was associated with improved quality of life compared with everolimus in patients with previously treated renal cell carcinoma.  

April 25th, 2016
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. 

March 24th, 2016
In a phase II trial of patients with metastatic clear cell renal cell carcinoma, everolimus was associated with better progression-free survival than apitolisib.

First | Prev | PAGE 1 of 8 | Next | Last